_220Progress
Recently Joined
🚫No Source Discussion🚫
Sharing log to document observations from two research subjects receiving ARA-290. The goal is simply to record dosing, tolerability, and any subjective or objective changes over time.
I hope this helps someone looking into ARA-290.
Please ask any questions or provide suggestions!
Compound - ARA-290
10 mg → 2 mL = 5 mg/mL (50 mcg/µL)
100 units (1.0 mL) = 5 mg
Subject A-73-year-old male
History:
Started conservatively with dose escalation.
Injection Log:
6/25 -1 mg (20 units) Left love handle
6/26- 2 mg (40 units) Left lower abdomen
6/27- 2 mg (40 units) Central lower abdomen
6/28-2 mg (40 units) Central right abdomen
Early Observations
History:
Unlike Subject A, Subject B experienced immediate injection-site discomfort.
Reported after injections:
At present, Subject B is considering discontinuing participation due to injection-site intolerance despite rotating injection locations.
Initial Notes
Although both subjects share neuropathy and chronic back pain, their local injection-site reactions have been markedly different despite using material from the same batch.
At this stage it is too early to comment on efficacy. Future updates will focus on:
This thread will be updated as additional data are collected.
Please share any history you have had with ARA-290 on this thread. Especially the injection site issues.
I hope this helps someone looking into ARA-290.
Please ask any questions or provide suggestions!
Compound - ARA-290
- 10 mg lyophilized vials
- Six vials from the same production batch (matching COAs and batch numbers)
- Five vials reconstituted with 2 mL phosphate-buffered saline (PBS)
- One vial reconstituted with 2 mL bacteriostatic water for comparison
10 mg → 2 mL = 5 mg/mL (50 mcg/µL)
100 units (1.0 mL) = 5 mg
Subject A-73-year-old male
History:
- Parkinson’s disease
- Peripheral neuropathy
- Chronic mid- and lower-back pain
Started conservatively with dose escalation.
- Day 1: 1 mg
- Days 2–4: 2 mg daily
- Day 5 onward: 4 mg daily
Injection Log:
6/25 -1 mg (20 units) Left love handle
6/26- 2 mg (40 units) Left lower abdomen
6/27- 2 mg (40 units) Central lower abdomen
6/28-2 mg (40 units) Central right abdomen
- Subject noted walking approximately 6 minutes before back pain began.
Early Observations
- No injection-site irritation.
- No redness, swelling, or discomfort reported.
- Dose escalation to 4 mg began June 29 and will continue for further observation.
History:
- Chronic neuropathic pain following ankle tendon surgery
- Chronic mid- and lower-back pain
- Started directly at 4 mg daily.
- Initial injection administered subcutaneously in the abdomen.
Unlike Subject A, Subject B experienced immediate injection-site discomfort.
Reported after injections:
- Burning/“fire” sensation
- Pain during and after administration
- Raised welt at the injection site
At present, Subject B is considering discontinuing participation due to injection-site intolerance despite rotating injection locations.
Initial Notes
Although both subjects share neuropathy and chronic back pain, their local injection-site reactions have been markedly different despite using material from the same batch.
At this stage it is too early to comment on efficacy. Future updates will focus on:
- Neuropathic pain
- Back pain
- Mobility
- Walking tolerance
- Sleep quality
- Injection-site reactions
- Any adverse events or unexpected observations
This thread will be updated as additional data are collected.
Please share any history you have had with ARA-290 on this thread. Especially the injection site issues.